| Document |
Document Title |
|
WO/2019/186133A1 |
Title: PRO-COAGULANT HISTONES Text:The present invention relates to modified histone proteinsfor use in promoting coagulation, wherein the modified histone protein has reduced cytotoxicity as compared to a corresponding wild-type histone...
|
|
WO/2019/185828A1 |
The present invention relates to a fusion protein comprising an Ixodes ricinus salivary gland polypeptide. In particular, the present invention relates to a fusion protein comprising at least one Ixodes ricinus salivary gland polypeptide...
|
|
WO/2019/183364A1 |
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further ...
|
|
WO/2019/178416A1 |
Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci in cells and increasing expression of fetal hemoglobin.
|
|
WO/2019/177163A1 |
This application provides: a novel mouse artificial chromosome vector that is stable in rodent cells or tissues or rodent individuals, specifically a mouse artificial chromosome vector derived from a mouse chromosome selected from the gr...
|
|
WO/2019/178526A1 |
Described herein are methods and compositions for reducing coagulation, e.g., in a subject having a coagulation disease or disorder. Aspects of the invention relate to administering to a subject a recombinant SmNPP-5 protein or pharmaceu...
|
|
WO/2019/173839A1 |
The present invention concerns methods comprising co-administration of pegfilgrastim and romiplostim for treatment of diseases and conditions characterized by low neutrophil levels (neutropenia) and/or low platelet levels (thrombocytopen...
|
|
WO/2019/172369A1 |
The present invention provides a novel composition for preventing or inhibiting hemorrhagic vasculopathy. More specifically, there is provided a composition for preventing or inhibiting hemorrhagic vasculopathy, the composition containin...
|
|
WO/2019/173654A2 |
Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci in cells and increasing expression of fetal hemoglobin.
|
|
WO/2019/168177A1 |
Provided is a novel anticancer drug combination therapy. This cancer prophylactic or therapeutic agent is obtained by combining: (A) panobinostat or a salt thereof; and (B) a tubulin inhibitor.
|
|
WO/2019/168063A1 |
The present invention provides a means which can appropriately control the balance between water and sodium in peritoneal dialysis therapies while avoiding adverse effects on the residual renal function and without causing hyponatremia. ...
|
|
WO/2019/163822A1 |
Provided is a method for producing a granular composition which is improved in the elution of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyl- oxy}-N-(methylsulfonyl)acetamide. The method for producing the granular composition ...
|
|
WO/2019/163994A1 |
The present invention addresses the problem of providing: a novel hemopoiesis-enhancing agent; and a drug for preventing or treating anemia, particularly intractable anemia, which contains the hemopoiesis-enhancing agent as an active ing...
|
|
WO/2019/158359A1 |
The present invention relates to a compound having the structure of Formula (I) for use in the prevention or treatment of a blood disorder, in particular by the modulation of von Willebrand factor levels. A nutraceutical product or food ...
|
|
WO/2019/153198A1 |
An application of synthetic vivianite particles as an oral iron supplement, comprising forming, by means of co-precipitation, porous pvivianite particles having no excipient. The iron in the body can be increased after the pvivianite par...
|
|
WO/2019/154363A1 |
A compound represented by formula (I) or an isomer or pharmaceutically acceptable salt thereof. The present invention also relates to an application of the same in preparing a drug for treating a disease related to a PGI2 receptor.
|
|
WO/2019/156210A1 |
Provided is a composition for improving lymphatic circulation, said composition comprising, as an active ingredient, a component selected from among a highly unsaturated fatty acid, a salt thereof and an ester thereof. Also provided is a...
|
|
WO/2019/153325A1 |
The present invention discloses the application of an artemisinin derivative in the preparation of a medicament for preventing and treating type 2 diabetes and complications thereof, and a pharmaceutical composition containing the artemi...
|
|
WO/2019/156199A1 |
The present invention addresses the problem of providing a novel drug for the prevention of autoimmune diseases, the suppression of the progression of the symptoms of autoimmune diseases, the suppression of the recurrence of autoimmune d...
|
|
WO/2019/156541A1 |
The present invention relates to a composition for increasing the expression of a blood coagulation factor gene, the composition comprising core-shell structured microparticles as an active ingredient. When administered in vivo along wit...
|
|
WO/2019/157268A1 |
The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
|
|
WO/2019/156540A1 |
The present invention relates to a composition for increasing the expression of a growth factor gene, the composition comprising core-shell structured microparticles as an active ingredient. When administered in vivo along with a gene, t...
|
|
WO/2019/154867A1 |
The present invention is based on the finding that administration of polypeptides comprising two immunoglobulin single variable domains (ISVD) against von Willebrand Factor (vWF) to human patients with an intial episode of thrombotic thr...
|
|
WO/2019/150196A1 |
Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for creating permanent changes to the genome that can result in at least one deletion, insertion, modulation, or in...
|
|
WO/2019/151941A1 |
A process for preparing cangrelor tetrasodium comprising: a) reacting a compound of formula M1 with morpholine to form a compound of formula M2; and b) reacting the compound of formula M2 with ciodronic acid to provide cangrelor tetrasodium
|
|
WO/2019/148246A1 |
This invention relates generally to therapeutic parenteral formulations comprising particular substituted pyridine based compounds, their manufacture, and methods and uses of said formulations in treating elevated intracranial pressure f...
|
|
WO/2019/151241A1 |
The present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt of the compound. (In the formula, X and Y may be the same or different, and each represents a hydrogen atom, a halogen atom, a C1-...
|
|
WO/2019/150050A1 |
The present invention relates to dimers of factor X variants, and the use thereof for the treatment of blood coagulation disorders.
|
|
WO/2019/149906A1 |
The present invention relates to a protein or polypeptide comprising an Ixodes ricinus salivary gland polypeptide, a fragment or a variant thereof, and its use for inhibiting the extrinsic coagulation pathway and for treating and/or prev...
|
|
WO/2019/151514A1 |
Provided is a monocyte differentiation inducer which contains albendazole as an active ingredient.
|
|
WO/2019/151450A1 |
When performing actual transplantation into a body for the purpose of regenerative medicine, advanced safety measures are necessary in sterilization treatment or the packaging process, and a large burden is placed on a practitioner when ...
|
|
WO/2019/149205A1 |
The present invention relates to a benzoheteroaryl derivative and a preparation method and medical application thereof. In particular, the present invention relates to a novel benzoheteroaryl derivative represented by general formula (I)...
|
|
WO/2019/150203A1 |
Materials and methods for treating a patient with hemoglobinopathy, both ex vivo and in vivo and materials and methods for deleting at least a portion of a human beta globin locus on chromosome 11 in a human cell by genome editing and th...
|
|
WO/2019/149158A1 |
The present invention relates to nitrogenous tricyclic compounds and uses thereof in medicine, in particular, the present invention discloses a novel nitrogenous tricyclic compound used as an FXR active regulator and a stereoisomer, a ge...
|
|
WO/2019/144412A1 |
Disclosed is a use of oral iron particles. By means of a chemical reduction method, the oxidation-reduction of ferric chloride and sodium borohydride generates zero-valent iron particles. The size of said particles is on the nanometer sc...
|
|
WO/2019/147615A1 |
Disclosed herein are methods of reducing or preventing thrombocytopenia, in a clinically relevant manner, that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject. Also disclosed is the administration ...
|
|
WO/2019/146676A1 |
The present invention pertains to a nucleic acid aptamer which comprises a base sequence selected from SEQ ID NOS: 11 to 20 and a medicinal composition for inhibiting blood clotting which contains the nucleic acid aptamer.
|
|
WO/2019/144811A1 |
The present invention relates to a tetrahydroisoquinoline derivative as shown in formula (I) and a preparation method therefor and the use thereof, and in particular to a tetrahydroisoquinoline derivative, a pharmaceutically acceptable s...
|
|
WO/2019/141274A1 |
A metal frame compound nanocarrier delivery system for targeting an active CD44 molecule, a preparation method therefor and uses thereof. The surface of the nanosized carrier is partially modified by a targeting ligand, wherein the targe...
|
|
WO/2019/141266A1 |
A hydrogel nanocarrier delivery system for targeting active CD44 molecule, and a preparation method therefor. The surface of the nanosized carrier is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that...
|
|
WO/2019/141276A1 |
A mesoporous hollow SiO2 nanocarrier delivery system for targeting an active CD44 molecule, a preparation method therefor, and uses thereof. The surface of the nano-sized carrier is partially modified by a targeting ligand, wherein the t...
|
|
WO/2019/141264A1 |
A dendritic polymer carrier delivery system for targeting an active CD44 molecule, a preparation method therefor, and uses thereof. The surface of the nanosized carrier is partially modified by a targeting ligand, wherein the targeting l...
|
|
WO/2019/141275A1 |
A silica nanocarrier delivery system for targeting an active CD44 molecule, and a preparation method therefor. The surface of the nanosized carrier is partially modified by a targeting ligand, wherein the targeting ligand is a ligand tha...
|
|
WO/2019/141267A1 |
A recombinant bionic nanocarrier delivery system for targeting an active CD44 molecule. The surface of the nanosized carrier is partially modified by a targeting ligand, wherein the targeting ligand is a ligand that can specifically bind...
|
|
WO/2019/141265A1 |
A micelle nanocarrier delivery system for targeting an active CD44 molecule, a preparation method therefor, and uses thereof, The surface of the nano-sized carrier is partially modified by a targeting ligand, wherein the targeting ligand...
|
|
WO/2019/143273A1 |
The present invention relates to the chemistry of organic compounds, pharmacology and medicine, and specifically to novel compounds, pharmaceutically acceptable salts thereof and pharmaceutical compositions thereof which are effective as...
|
|
WO/2019/142941A1 |
Provided is a method of producing, by means of a simple drying operation, high-purity ferric citrate which retains a high specific surface area while having a reduced water soluble organic solvent content. This method of producing ferric...
|
|
WO/2019/141278A1 |
A nanosized calcium carrier delivery system for targeting an active CD44 molecule, a preparation method therefor, and uses thereof. The surface of the nanosized carrier is partially modified by a targeting ligand, wherein the targeting l...
|
|
WO/2019/134971A1 |
The present invention relates to encapsulated particles, wherein the particles comprise one or more pharmaceutically active ingredients and optionally one or more pharmaceutically acceptable excipients and wherein the particles are encap...
|
|
WO/2019/134510A1 |
Disclosed is a short peptide quaternary ammonium salt compound and a use thereof. In particular, disclosed is a type of short peptide quaternary ammonium salt compound or a stereoisomer, polymorph, solvate thereof, or a metabolite, prodr...
|
